^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IP-001

    i
    Other names: IP-001, N-dihydro-galacto-chitosan
    Associations

    News

    Trials
    Company:
    Immunophotonics
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    12d
    INJECTABL-3: Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases (clinicaltrials.gov)
    P2/3, N=717, Not yet recruiting, Immunophotonics, Inc.
    New P2/3 trial
    |
    IP-001
    20d
    SAKK 66/17: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=28, Completed, Swiss Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Jul 2025 | Trial primary completion date: Dec 2025 --> Jul 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    IP-001
    6ms
    SAKK 66/17: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=28, Active, not recruiting, Swiss Cancer Institute | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    IP-001
    10ms
    SAKK 66/17: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=28, Active, not recruiting, Swiss Group for Clinical Cancer Research | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    IP-001
    11ms
    Enhancing the Immunotherapeutic Effect by IP-001 and Irreversible Electroporation in Mouse Oligometastatic Models of Pancreatic Adenocarcinoma. (PubMed, Ann Surg Oncol)
    The study provided compelling evidence for the efficacy of IRE&IP-001 therapy in suppressing pancreatic tumors, including off-target oligometastatic lesions. The observed off-target effect underscores the importance of systemic immune activation in achieving effective tumor control.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    IP-001
    12ms
    N-Dihydrogalactochitosan Drives Conventional and Alternative Activations of STING to Synergize Type I IFN and IL-1β Productions for Antitumor Immunity. (PubMed, Adv Funct Mater)
    Our findings demonstrate that GC acts as a multimodal immune stimulant via STING to generate a broad type I IFN response. This uniquely broad response holds therapeutic promise in generating enhanced antitumor and antiviral immunities.
    Journal
    |
    STING (stimulator of interferon response cGAMP interactor 1) • IL1B (Interleukin 1, beta)
    |
    IP-001
    1year
    INJECTABL-1: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (clinicaltrials.gov)
    P1/2, N=42, Active, not recruiting, Immunophotonics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IP-001
    1year
    Enhancing the Immunotherapeutic Effect by IP-001 and Irreversible Electroporation in Mouse Oligometastatic Models of Pancreatic Adenocarcinoma. (PubMed, Ann Surg Oncol)
    The study provided compelling evidence for the efficacy of IRE&IP-001 therapy in suppressing pancreatic tumors, including off-target oligometastatic lesions. The observed off-target effect underscores the importance of systemic immune activation in achieving effective tumor control.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    IP-001
    over1year
    Thermal ablation enhances immunotherapeutic effect of IP-001 on orthotopic liver cancer in a rat model. (PubMed, Int J Hyperthermia)
    Combination of MWA and IP001 enhances tumor suppression in an orthotopic HCC rat model. The tumor suppression is associated to the enhanced immune responses in terms of recruiting the important cell subpopulations such as CD8 + T-cells and NK cells into tumor microenvironment and abolishing immune suppressor such as Treg cells.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    IP-001
    over1year
    INJECTABL-1: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (clinicaltrials.gov)
    P1/2, N=44, Recruiting, Immunophotonics, Inc. | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    IP-001
    2years
    INJECTABL-1: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (clinicaltrials.gov)
    P1/2, N=44, Recruiting, Immunophotonics, Inc. | Phase classification: P1b/2a --> P1/2
    Phase classification
    |
    IP-001
    almost3years
    SAKK 66/17: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=39, Recruiting, Swiss Group for Clinical Cancer Research | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Jun 2023 --> Jun 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    IP-001